A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Sağlık ve TıpOne-Off2yManifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel topluluk tahminiEvet 71.7%
Tahminciler
6
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
17 saat önce güncellendi
Guncelligini yitirmis25 Nis 23 16:13 UTC2 Oca 29 06:59 UTC
Trendler
Kurallar
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
